A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.

ABSTRACT:

Rationale

Animal and human studies support the importance of the coagulation cascade in pulmonary fibrosis.

Objectives

In a cohort of subjects with progressive idiopathic pulmonary fibrosis (IPF), we tested the hypothesis that treatment with warfarin at recognized therapeutic doses would reduce rates of mortality, hospitalization, and declines in FVC.

Methods

This was a double-blind, randomized, placebo-controlled trial of warfarin targeting an international normalized ratio of 2.0 to 3.0 in patients with IPF. Subjects were randomized in a 1:1 ratio to warfarin or matching placebo for a planned treatment period of 48 weeks. International normalized ratios were monitored using encrypted home point-of-care devices that allowed blinding of study therapy.

Measurements

SUBMITTER: Noth I 

PROVIDER: S-EPMC3400994 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature